Saniona ABCHIX:SANIOS 66 PS Ratio is 4.09 as of Jul. 08, 2026, which is 74% below its 10-year median of 15.70. GuruFocus rates CHIX:SANIOS with a GF Score™ of 66/100 and a GF Value™ of kr26.73 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 928 Biotechnology companies, Saniona AB ranks better than 71.77% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Saniona AB's share price is kr12.75.
Saniona AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr3.12. Hence, Saniona AB's PS Ratio for today is 4.09.
The historical rank and industry rank for Saniona AB's PS Ratio or its related term are showing as below:
CHIX:SANIOs'
s PS Ratio Range Over the Past 10 Years
Min: 1.96 Med: 15.7 Max: 144.23
Current: 4.27
During the past 13 years, Saniona AB's highest PS Ratio was 144.23. The lowest was 1.96. And the median was 15.70.
CHIX:SANIOs's PS Ratio is ranked better than 71.77% of 928
companies
in the Biotechnology industry
Industry Median: 9.59
vs CHIX:SANIOs: 4.27
Saniona AB revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Saniona AB was 4.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 151.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 100.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -0.40% per year.
During the past 13 years, Saniona AB's highest 3-Year average Revenue per Share Growth Rate was 180.10% per year. The lowest was -59.10% per year. And the median was 11.10% per year.
Back to Basics: PS Ratio
Saniona AB (CHIX:SANIOs) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Saniona AB PS Ratio Related Terms
Saniona AB PS Ratio Historical Data
* Premium members only.
The historical data trend for Saniona AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:SANIOS vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, Saniona AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Saniona AB PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Saniona AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Saniona AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Saniona AB's Share Price of today is kr12.75. Saniona AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr3.12.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Saniona AB (CHIX:SANIOS) has a PS Ratio of 4.09 as of Jul. 08, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Saniona AB and its competitors. This is 74% below median its historical median of 15.70. Over the past decade, Saniona AB's PS Ratio has ranged from 1.96 to 144.23. According to the industry distribution chart, Saniona AB ranks #262 out of 928 companies in the Biotechnology industry, placing it in the top 28.2%.
Is Saniona AB's PS Ratio too high?
Saniona AB's current PS Ratio of 4.09 is 74% below median its 10-year median of 15.70. Over the past 10 years, this metric has ranged from a low of 1.96 to a high of 144.23. The Biotechnology industry median PS Ratio is 9.59. Saniona AB's value of 4.09 is 57.4% below this industry median. Based on the distribution chart, Saniona AB ranks #262 out of 928 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Saniona AB has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Saniona AB's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Saniona AB ranks #262 out of 928 companies for PS Ratio. This puts Saniona AB in the upper half of its industry. The industry median PS Ratio is 9.59. Saniona AB's value of 4.09 is 57.4% below this benchmark. Historically, Saniona AB's own PS Ratio has ranged from 1.96 to 144.23 over the past decade. While the company's 10-year median is 15.70 vs. the industry median of 9.59, Saniona AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.59, based on 928 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Saniona AB's current PS Ratio of 4.09 is 57.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Saniona AB and its competitors. For the Biotechnology industry, the median PS Ratio is 9.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Saniona AB's current PS Ratio is 4.09, which is 74% below median its own 10-year median of 15.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Saniona AB stock overvalued right now?
Based on GuruFocus' analysis, Saniona AB (CHIX:SANIOS) is currently considered Significantly Undervalued. The stock's GF Value™ is kr26.73, compared to a current price of kr12.75 — trading 52.3% below its estimated fair value. The current PS Ratio is 4.09, which is 74% below median its 10-year median of 15.70 and 57.4% below the Biotechnology industry median of 9.59. Saniona AB's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Saniona AB (CHIX:SANIOS), the current PS Ratio is 4.09 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Saniona AB (CHIX:SANIOS) Overvalued in 2026?
Based on GuruFocus' analysis, Saniona AB stock appears to be undervalued.
The current stock price of kr12.75 is trading 52.3% below its estimated GF Value™ of kr26.73.
GuruFocus considers Saniona AB to be Significantly Undervalued.
Key valuation signals for CHIX:SANIOS:
PS Ratio: 4.09 (74% below median its 10-year median of 15.70)
GF Value™: kr26.73 vs. price of kr12.75 (52.3% below fair value)
Industry Position: 57.4% below the Biotechnology median (#262 of 928)
No single metric tells the full story. See the CHIX:SANIOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Saniona AB researches and develops drugs for the treatment of diseases of the central nervous system, autoimmune diseases, metabolic diseases, and the treatment of pain. It develops a technology platform that enables the investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. The company product pipeline includes Tesomet, SAN711, Tesofensine, SAN903, and SAN2219. Geographically, it operates in USA, Sweden, Germany, Denmark, and United Kingdom, out of which it derives maximum revenue from USA.
66GF Score
Get the complete analysis for CHIX:SANIOS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:SANIOS has been successfully added to your 
